Health Care & Life Sciences » Pharmaceuticals | Zafgen Inc.

Zafgen Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
12.00
16.00
70.00
212.00
188.00
261
Gross Income
12.00
16.00
70.00
212.00
188.00
261
SG&A Expense
13,768.00
35,516.00
73,743.00
56,910.00
53,687.00
62,461
EBIT
13,780.00
35,532.00
73,813.00
57,122.00
53,875.00
62,722
Unusual Expense
-
-
-
1,403.00
24.00
-
Non Operating Income/Expense
247.00
104.00
105.00
18.00
140.00
237
Interest Expense
-
870.00
806.00
529.00
165.00
1,898
Pretax Income
14,027.00
36,478.00
74,286.00
58,178.00
52,928.00
62,968
Income Tax
-
-
-
300.00
900.00
1,600
Consolidated Net Income
14,027.00
36,478.00
74,286.00
57,878.00
52,028.00
61,368
Net Income
14,027.00
36,478.00
74,286.00
57,878.00
52,028.00
61,368
Net Income After Extraordinaries
14,027.00
36,478.00
74,286.00
57,878.00
52,028.00
61,368
Net Income Available to Common
14,240.00
36,570.00
74,286.00
57,878.00
52,028.00
61,368
EPS (Basic)
0.54
3.00
2.78
2.12
1.90
1.90
Basic Shares Outstanding
26,135.00
12,189.20
26,756.10
27,297.90
27,433.20
32,228.70
EPS (Diluted)
0.54
3.00
2.78
2.12
1.90
1.90
Diluted Shares Outstanding
26,135.00
12,189.20
26,756.10
27,297.90
27,433.20
32,228.70
EBITDA
13,768.00
35,516.00
73,743.00
56,910.00
53,687.00
62,461
Non-Operating Interest Income
-
28.00
438.00
894.00
996.00
1,889
Preferred Dividends
213.00
92.00
-
-
-
-

About Zafgen

View Profile
Address
175 Portland Street
Boston Massachusetts 02114
United States
Employees -
Website http://www.zafgen.com
Updated 07/08/2019
Zafgen, Inc. is a biopharmaceutical company, which is engages in the development of therapeutics for both rare and prevalent metabolic diseases including type 2 diabetes, Prader-Willi syndrome, or PWS, and potentially other metabolically related disorders. It offers the ZGN-1061, a novel fumagillin-class MetAP2 inhibitor administered by subcutaneous injection, which is currently being profiled for its utility in the treatment of type 2 diabetes. The company was founded on November 22, 2005 and is headquartered in Boston, MA.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.